{
    "nct_id": "NCT05144841",
    "official_title": "A Phase 2 Open-label Clinical Study to Evaluate the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-004)",
    "inclusion_criteria": "* Has relapsed or refractory (rr) DLBCL; has progressed after at least 2 lines of prior therapy; and has progressed after auto- stem cell transplant (SCT) or are auto-SCT ineligible. Must have received prior multiagent regimen that includes an alkylating agent. anthracycline, and anti-CD20 (cluster of differentiation 20) monoclonal antibody.\n* Has histologically confirmed diagnosis of DLBCL.\n* Has radiographically measurable DLBCL per the Lugano Response Criteria.\n* Should either be post- chimeric antigen receptor T cell therapy (CAR-T) failure or ineligible for CAR-T (for any reason).\n* Life expectancy of at least 3 months.\n* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 assessed within 7 days before time of enrollment.\n* Has adequate organ function.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Has received a diagnosis of Primary mediastinal B-cell lymphoma (PMBCL).\n* Has undergone solid organ transplant at any time.\n* Has a history of any clinically significant cardiovascular conditions within 6 months of screening or serious cardiac arrhythmia requiring medication.\n* Has known history of liver cirrhosis.\n* Has pericardial effusion or clinically significant pleural effusion.\n* Has ongoing Grade >1 peripheral neuropathy.\n* Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years.\n* Transformed DLBCL from indolent lymphoma.\n* In participants with prior allo-SCT, acute graft versus host disease (GVHD) or ongoing evidence of chronic GVHD.\n* Has received prior systemic anticancer therapy, including investigational agents within 4 weeks prior to the first dose of study intervention.\n* Has received prior radiotherapy within 28 days of start of study intervention. Participants.\n\nmust have recovered from all radiation-related toxicities.\n\n* Has ongoing corticosteroid therapy (exceeding 30 mg daily of prednisone equivalent).\n* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention.\n* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention.\n* Has known active central nervous system (CNS) lymphoma involvement or active CNS involvement by lymphoma.\n* Has an active infection requiring systemic therapy.\n* Has a known history of human immunodeficiency virus (HIV) infection.\n* Has a known history of hepatitis B or known active hepatitis C virus (HCV).",
    "miscellaneous_criteria": ""
}